Concepedia

Author

Jindřich Kopecký

University Hospital Hradec KrálovéORCID

Also Known As

F. Sakakibara, J Kopecky, J Kopecký, J. KOPECKY, J. Kopecky, J. Kopecký, JINDRICH KOPECKY, JINDRICH KOPECKÝ, Jindrich KOPECKY, Jindrich Kopecky

146

Publications

1.1K

Citations

18

H-Index

33

Concepts

All Affiliations

University Hospital Hradec KrálovéCharles UniversityThomayer University HospitalIstituti di Ricovero e Cura a Carattere ScientificoHôpital de Jolimont
JK

About

Jindřich Kopecký is an author at University Hospital Hradec Králové specializing in medicine, oncology, and urology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

250

2

Nursing

2

2

29

3

Immunology

2

2

50

4

Social Sciences

1

1

11

5

Neurology

1

1

21

Jindřich Kopecký

×

24

Publications

548

Citations

16

H-Index

YearCitations

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report

Jindřich Kopecký, Ondřej Kubeček, Tomáš Geryk,

Journal of Medical Case Reports

2018

53

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

Matteo Santoni, Sebastiano Buti, Zin Myint,

European Urology Oncology

2023

52

Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic

Davide Mauri, Konstantinos Kamposioras, Maria Tolia,

The Lancet Oncology

2020

39

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Matteo Santoni, Francesco Massari, Zin Myint,

Targeted Oncology

2023

34

Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma

Šárka Lukešová, V. Vroblova, J Tošner,

Współczesna Onkologia

2015

31

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Marc‐Oliver Grimm, Emilio Esteban, Philippe Barthélémy,

The Lancet Oncology

2023

29

Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report

Ondřej Kubeček, T. Soukup, Adam Paulík,

BMC Cancer

2016

27

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Matteo Santoni, Francesco Massari, Zin Myint,

Clinical Genitourinary Cancer

2023

26

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Ondřej Fiala, Sebastiano Buti, Hideki Takeshita,

Cancer Immunology Immunotherapy

2023

26

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

L. Bergmann, Laurence Albigès, Marit Ahrens,

Annals of Oncology

2025

24

Page 1